LivaNova PLC
About LivaNova PLC
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $1.4B
- Net income
- -$242.5M
- Total assets
- $2.6B
- Market cap
- $4.0B
- Gross margin
- 67.7%
- Operating margin
- 14.4%
- Net margin
- -17.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $1.4B
- Cost of revenue
- $448.2M
- Gross profit
- $939.9M
- Operating expenses
- $740.5M
- Operating income
- $199.4M
- Income tax
- $21.6M
- Net income
- -$242.5M
- EPS (basic)
- $-4.45
- EPS (diluted)
- $-4.45
Balance sheet
- Total assets
- $2.6B
- Current assets
- $1.1B
- Total liabilities
- $1.4B
- Current liabilities
- $808.1M
- Shareholders’ equity
- $1.2B
Cash flow
- Operating cash flow
- $254.3M
- Investing cash flow
- -$72.9M
- Financing cash flow
- -$285.7M
- Net cash flow
- -$88.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $4.0B
- EPS (diluted)
- $-4.45
- Shares outstanding
- 53.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 10, 1993
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $242.5M in FY2025.
- Revenue grew 34% from FY2021 to FY2025.
- Gross margin of 67.7%, net margin -17.5%.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review LivaNova PLC.
Write a review
News about LivaNova PLC
News & sentiment via Polygon.io
